Bio-Techne Corporation (TECH)
Techne (TECH) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is the Options Market Predicting a Spike in BioTechne Stock?
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Techne (TECH) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago.
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?
Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bio-Techne Opens New Customer Experience Centre in Germany
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
TECH Stock Might Rise Following the Leo Shipping Announcement
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
